ICON Public (NASDAQ:ICLR – Get Rating) is scheduled to be announcing its earnings results before the market opens on Thursday, April 28th. Analysts expect the company to announce earnings of $2.48 per share for the quarter. ICON Public has set its FY22 guidance at $11.55-11.95 EPS and its FY 2022 guidance at $11.550-$11.950 EPS.
ICON Public (NASDAQ:ICLR – Get Rating) last announced its earnings results on Tuesday, February 22nd. The medical research company reported $2.44 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.40 by $0.04. ICON Public had a return on equity of 12.71% and a net margin of 2.79%. The business had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.90 billion. During the same quarter last year, the firm earned $1.90 EPS. ICON Public’s revenue for the quarter was up 148.0% compared to the same quarter last year. On average, analysts expect ICON Public to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.
NASDAQ:ICLR opened at $210.67 on Wednesday. The company has a market cap of $17.15 billion, a P/E ratio of 71.41, a price-to-earnings-growth ratio of 1.32 and a beta of 0.98. ICON Public has a twelve month low of $204.80 and a twelve month high of $313.00. The business has a 50 day moving average price of $236.56 and a two-hundred day moving average price of $262.75. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.67.
An institutional investor recently bought a new position in ICON Public stock. Titleist Asset Management LTD. bought a new position in shares of ICON Public Limited (NASDAQ:ICLR – Get Rating) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 648 shares of the medical research company’s stock, valued at approximately $201,000. Institutional investors and hedge funds own 88.40% of the company’s stock.
About ICON Public (Get Rating)
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
- Get a free copy of the StockNews.com research report on ICON Public (ICLR)
- Microsoft (NASDAQ: MSFT) Saves The Day, For Now
- Las Vegas Sands Stock Could be a Winning Bet Down Here
- Newmont Corporation is the Same as It’s Always Been Which is Why It’s a Buy
- The Sherwin-Williams Company Bottoms Above Institutional Support
- Simpson Manufacturing Co. Hits The Nail On The Head, Again
Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.